A cure is defined as a sustained virologic response (SVR) for a certain period (usually 12 weeks) and is usually written as SVR12
(Nasdaq: GILD) today announced data from two Phase 2 studies and a compassionate access study in
Sofosbuvir has a number of ideal properties, including once-daily dosing, no meal
Drug Images Sovaldi (sofosbuvir) is a prescription drug that’s used to treat hepatitis C
1586/17512433
The safety and efficacy of Sovaldi in paediatric patients aged 3 years and above are based on data from 106 patients who were treated with Sovaldi
caution advised w/ narrow therapeutic index drugs extensively metabolized in the liver; viral eradication may improve hepatic metabolic function, decr
See full prescribing information for SOVALDI
SOVALDI is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of: • Patients with HCV/HIV-1 coinfection: Safety and efficacy have been studied
1 interaction
Sovaldi provides the first interferon-free treatment option for chronic hepatitis C
Gilead Sciences, Inc
The safety, pharmacokinetics, and efficacy of SOVALDI in pediatric patients 12 years of age and older or weighing at least 35 kg with genotype 2 and 3 infection have been established
See also Warning section
2) To treat the entire market, Sovaldi would cost $365 billion dollars, a sum comparable to total Medicaid spending for 2013, as shown in Figure 3
Harvoni and Sovaldi are each approved in the United States for the treatment of chronic HCV infection
Sofosbuvir (Sovaldi): Sofosbuvir is Indicated for the Treatment of Chronic Hepatitis C Virus (CHC) Infection in Adult Patients With Compensated Liver Disease, Including Cirrhosis [Internet]
Sovaldi is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon
Given the increased clinical efficacy of Sovaldi, Gilead believed that it was more than justified in using the cost-per-cure pricing model [37, 46]
SOVALDI was evaluated in an open-label clinical trial (Study 1112), which included 106 subjects (31 genotype 2; 75 genotype 3) 3 years of age and older